IP Library Granted Patent US 8,603,752
Granted Patent B2
US 8,603,752 · App. 13/023,366 · Granted Dec 10, 2013

Methods for identifying and monitoring drug side effects

Inventors: Leroy Hood (Seattle, WA); Biaoyang Lin (Bothell, WA)
Assignee: Institute for Systems Biology
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,603,752
App. No.
13/023,366
Granted
Dec 10, 2013
Kind
B2
Abstract

The present invention relates generally to methods for identifying drug side effects by detecting perturbations in organ-specific molecular blood fingerprints. The invention further relates to methods for identifying drug-specific organ-specific molecular blood fingerprints. As such, the present invention provides compositions comprising organ-specific proteins, detection reagents for detecting such proteins, and panels and arrays for determining organ-specific molecular blood fingerprints.

Claims (10)

1. A method for determining the presence or absence of a drug side effect in a subject taking a drug for which a first organ is expected to be the therapeutic target wherein said side effect is associated with a second organ different from said first organ and wherein said second organ is not the therapeutic target of the drug comprising,

(a) detecting a level of each of a plurality of organ-specific proteins in a test blood sample from the subject, wherein the plurality of organ-specific proteins are secreted from said second organ;

(b) comparing said level of each of the plurality of said organ-specific proteins in said test blood sample to a level of each of the plurality of said organ-specific proteins in a control sample of blood from one or more subjects who have not taken said drug wherein the organ-specific proteins comprises at least 5 organ-specific proteins;

wherein a statistically significant altered level of one or more of the plurality of said organ-specific proteins in the test blood sample as compared to said control sample is indicative of the presence of a drug side effect in said subject.

2. The method of claim 1 wherein the level of each of the plurality of organ-specific proteins is detected using a method which is mass spectrometry, or an immunoassay.

3. The method of claim 2 wherein the level of each of the plurality of organ-specific proteins is measured using tandem mass spectrometry, or using ELISA or using an antibody array.

4. The method of claim 1 wherein the organ-specific proteins comprise liver-specific proteins, lung-specific proteins or kidney-specific proteins.

5. The method of claim 1 wherein the organ-specific proteins comprise at least 10 organ-specific proteins.

6. The method of claim 1 wherein the organ-specific proteins comprise at least 20 organ-specific proteins.

7. The method of claim 4 wherein the organ-specific proteins are lung-specific proteins.

Assignments (4)
SECURITY AGREEMENT Recorded Nov 22, 2022
From: BIODESIX, INC.
To: PERCEPTIVE CREDIT HOLDINGS IV, LP
Reel/Frame 061977/0919 →
RELEASE OF SECURITY INTEREST Recorded Aug 12, 2020
From: IND FUNDING LLC
To: INTEGRATED DIAGNOSTICS, INC.
Reel/Frame 053476/0137 →
SECURITY INTEREST IN RIGHTS UNDER A LICENSE AGREEMENT IN WHICH LISTED PATENTS ARE LICENSED Recorded Apr 29, 2014
From: INTEGRATED DIAGNOSTICS, INC.
To: IND FUNDING LLC
Reel/Frame 032785/0261 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2011
From: HOOD, LEROY; LIN, BIAOYANG
To: INSTITUTE FOR SYSTEMS BIOLOGY
Reel/Frame 025812/0348 →
Continuity (5)
Continuation 12468834 · May 19, 2009
Continuation 11342367 · Jan 27, 2006
Provisional Application 60683004 · May 20, 2005
Provisional Application 60647792 · Jan 27, 2005
Related Publication 20110136690A1 · Jun 9, 2011